Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This disruption hampers the synthesis of purine nucleotides and thymidylate, leading to reduced DNA replication and cell division, particularly affecting rapidly dividing immune and cancer cells.

The specific dose of Methotrexate Accord is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and treatment goals. Only a qualified healthcare professional should set the dosage regimen.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Methotrexate is a widely used antimetabolite with a well‑characterized safety profile and multiple indications. Compared with newer agents such as pemetrexed or leflunomide, methotrexate is generally less expensive but may require more intensive monitoring for hepatic, renal, and hematologic toxicity.

Methotrexate Accord should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. If the solution reaches room temperature, it should be used promptly and not re‑refrigerated.

Methotrexate Accord is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intravenous routes. Administration is performed by qualified healthcare professionals in a clinical setting, following aseptic technique and appropriate dosing guidelines.

The most serious risks include bone marrow suppression leading to severe cytopenias, significant hepatic toxicity that can progress to fibrosis or cirrhosis, pulmonary fibrosis, and life‑threatening infections due to immunosuppression. Prompt monitoring and early detection are essential.

Methotrexate Accord should not be used by pregnant women, individuals with severe renal or hepatic impairment, patients with known hypersensitivity to methotrexate, or those receiving live vaccines without appropriate medical supervision.